2019 American Transplant Congress
Circulating Donor Specific Antibody and Biopsy C4d Positivity in Pancreas Rejection Increase the Probability of Earlier Return to Insulin after Rejection
*Purpose: Outcome data following rejection in pancreas recipients are sparse. We sought to study the influence of C4d positivity and the presence of circulating DSA…2019 American Transplant Congress
A Prognostic Biomarker to Estimate the Likelihood of Developing De Novo Donor Specific Antibody in Kidney Transplant Recipients
*Purpose: Evaluation of human leukocyte antigen (HLA) mismatch at antibody epitope level rather than antigen level may explain better the impact of HLA mismatch on…2019 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
*Purpose: To determine the development of de novodonor specific antibodies (DSA) in renal transplant recipients with immunosuppression modulation and BK viremia and the associated risk…2019 American Transplant Congress
Belatacept Monotherapy in Kidney Transplant Recipients with Failed Allografts Reduces Humoral Sensitization in a Single Center Randomized Controlled Trial
Emory University School of Medicine, Atlanta, GA
*Purpose: Kidney transplant recipients with failed allografts suffer from high rates of humoral sensitization. Immunosuppression (IS) strategies are highly variable in these patients with many…2019 American Transplant Congress
Next Gen ABO Antibody Assessment: Development of a Bead-Based ABO Antibody Detection Assay
*Purpose: Accurate characterization of ABO antibodies (ABO-Ab) is critical to assess their impact in ABO incompatible (ABOi) transplantation. The current ABO-Ab detection method using erythrocyte…2019 American Transplant Congress
ABMR In Low-single Dose Thymoglobulin Induction Protocol In Renal Transplant Recepients From A Tertiary Care Centre In A Developing Country
*Purpose: Fool proof induction therapy in low sensitized patients is still elusive. There is a thin line between over immunosuppression and infection . Conventional rabbit…2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…2019 American Transplant Congress
Human Leukocyte Antigen Class I (HLA-I) Antibodies in Patients Undergoing Liver Transplantation: Implications for Platelet Transfusion Support
*Purpose: Liver transplantation is a high platelet transfusion (PLT) setting due to the elevated incidence of thrombocytopenia and bleeding. HLA-I antibodies are thought to have…2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…2019 American Transplant Congress
Not All Donor-Specific Antibodies Are Equal: Predictors of Risk of Chronic Lung Allograft Dysfunction
*Purpose: Donor-specific HLA antibodies (DSA) have been previously associated with chronic lung allograft dysfunction (CLAD). However, the DSA characteristics that predict risk of CLAD are…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 40
- Next Page »